Equities

CorVel Corp

CRVL:NSQ

CorVel Corp

Actions
  • Price (USD)275.69
  • Today's Change-4.43 / -1.58%
  • Shares traded34.87k
  • 1 Year change+36.49%
  • Beta1.1535
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CorVel Corporation is engaged in applying technology, including artificial intelligence, machine learning, and natural language processing designed to address the management of episodes of care and the related health-care costs. The Company's services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and Medicare services. It partners with employers, third party administrators (TPAs), insurance companies, and government agencies to assist its customers in managing the medical costs of workers compensation, group health, and auto insurance and in monitoring the quality of care provided to claimants. Its network solutions services include professional nurse review, expert fee negotiations, specialty networks, preferred provider organization management, medical bill repricing, automated adjudication, and electronic reimbursement. Its bill review services include coding review and re-bundling.

  • Revenue in USD (TTM)795.31m
  • Net income in USD76.25m
  • Incorporated1991
  • Employees4.44k
  • Location
    CorVel CorpSUITE 1020, 2010 MAIN STREEIRVINE 92614United StatesUSA
  • Phone+1 (949) 851-1473
  • Fax+1 (949) 851-1469
  • Websitehttps://www.corvel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Agilon Health Inc4.78bn-207.85m2.46bn1.12k--3.57--0.5149-0.5182-0.7111.781.682.13--3.714,283,411.00-9.27---20.91--6.37---4.35------0.0514--80.74---112.01------
Progyny Inc1.11bn61.26m2.55bn563.0044.044.5039.962.300.60710.607110.985.951.53--3.631,968,529.008.4811.5011.8816.0221.8921.485.536.64----0.000.0038.3459.52104.35--44.47--
Evolent Health Inc2.18bn-141.23m2.70bn4.70k--2.55--1.24-1.25-1.2519.2810.720.8316--6.30462,948.70-4.22-9.60-5.36-12.5920.5624.50-5.07-13.66---0.05480.3272--45.2625.65-660.71---6.18--
Irhythm Technologies Inc513.17m-129.96m2.82bn2.00k--31.20--5.49-4.22-4.2216.712.900.770910.857.37256,587.00-19.52-21.92-22.55-26.7766.9669.39-25.33-25.756.95-18.440.877--19.9027.32-6.24--50.82--
Quidelortho Corp2.86bn-1.76bn2.85bn7.10k--0.8603--0.9966-26.38-26.3842.8249.520.36962.678.92403,197.20-22.7911.34-25.5712.9148.1362.71-61.6520.930.8070.87860.42070.00-8.2141.83-101.84--45.87--
Amedisys Inc2.25bn-20.59m3.16bn19.00k--2.911,040.181.40-0.6446-0.644668.7333.301.12--6.89118,495.10-1.057.82-1.3810.3944.3943.63-0.94395.89--11.620.25610.000.5936.11-108.22--14.16--
Surgery Partners Inc2.79bn600.00k3.20bn10.50k8,286.191.6311.581.150.0030.00322.1415.480.410424.895.90266,142.802.331.173.201.6333.7326.335.673.031.562.470.4606--8.039.1478.21--17.41--
PACS Group Inc-100.00bn-100.00bn4.22bn32.43k--31.94----------0.8661----------------------------0.8608--28.47---25.00------
Radnet Inc1.66bn21.27m4.29bn7.87k178.774.9223.902.590.32480.324824.8311.810.6159--7.88210,591.101.861.242.391.6621.9321.563.021.86--1.730.43650.0013.0510.64-71.42-37.6319.60--
Select Medical Holdings Corp6.79bn259.99m4.42bn38.40k16.303.198.160.65152.092.0954.6210.650.8726--6.37176,767.904.264.195.265.4614.4413.984.895.11--3.780.697815.305.225.5753.0311.986.50--
CorVel Corp795.31m76.25m4.79bn4.44k63.7319.3462.706.024.404.4045.8514.491.87--8.93--17.9714.8730.7324.2121.5922.149.599.16--------10.685.9514.9010.57----
Option Care Health Inc4.43bn272.67m5.05bn5.81k19.103.5315.061.141.521.5224.808.221.3914.009.15763,044.908.553.6310.644.3522.3522.456.152.781.396.980.42640.009.0643.4277.40--24.72--
Acadia Healthcare Company Inc2.99bn-11.30m6.15bn23.50k--2.1245.992.05-0.1354-0.135432.7131.300.5667--8.17176,030.70-0.06532.32-0.07262.64-----0.11535.601.255.860.3843--12.208.99-107.93--3.34--
Ensign Group Inc3.85bn218.38m6.78bn35.30k31.384.3023.081.763.803.8066.9827.730.9431--8.00109,141.305.366.456.377.8821.5422.325.686.48--40.620.08586.5623.2716.28-6.8028.624.405.02
Data as of May 23 2024. Currency figures normalised to CorVel Corp's reporting currency: US Dollar USD

Institutional shareholders

40.25%Per cent of shares held by top holders
HolderShares% Held
Kayne Anderson Rudnick Investment Management LLCas of 31 Mar 20241.90m11.14%
BlackRock Fund Advisorsas of 31 Mar 20241.30m7.62%
The Vanguard Group, Inc.as of 31 Mar 20241.09m6.37%
Renaissance Technologies LLCas of 31 Mar 2024670.31k3.92%
Dimensional Fund Advisors LPas of 31 Mar 2024573.14k3.35%
SSgA Funds Management, Inc.as of 31 Mar 2024352.91k2.06%
Boston Trust Walden, Inc.as of 31 Mar 2024278.70k1.63%
Neuberger Berman Investment Advisers LLCas of 31 Mar 2024272.85k1.60%
Geode Capital Management LLCas of 31 Mar 2024229.60k1.34%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024207.86k1.22%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.